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a b s t r a c t 
In skeletal muscle cells, GLUT1 is responsible for a large portion of basal uptake of glucose and dehydroascorbic 
acid, both of which play roles in antioxidant defense. We hypothesized that conditions that would decrease 
GLUT1-mediated transport would cause increased reactive oxygen species (ROS) levels in L6 myoblasts, while 
conditions that would increase GLUT1-mediated transport would result in decreased ROS levels. We found 
that the GLUT1 inhibitors fasentin and phloretin increased the ROS levels induced by antimycin A and the 
superoxide generator pyrogallol. However, indinavir, which inhibits GLUT4 but not GLUT1, had no effect on 
ROS levels. Ataxia telangiectasia mutated (ATM) inhibitors and activators, previously shown to inhibit and 
augment GLUT1-mediated transport, increased and decreased ROS levels, respectively. Mutation of an ATM 
target site on GLUT1 (GLUT1-S490A) increased ROS levels and prevented the ROS-lowering effect of the ATM 
activator doxorubicin. In contrast, expression of GLUT1-S490D lowered ROS levels during challenge with 
pyrogallol, prevented an increase in ROS when ATM was inhibited, and prevented the pyrogallol-induced 
decrease in insulin signaling and insulin-stimulated glucose transport. Taken together, the data suggest that 
GLUT1 plays a role in regulation of ROS and could contribute to maintenance of insulin action in the presence
of ROS. 
c © 2014 The Authors. Published by Elsevier B.V. 
This is an open access article under the CC BY license 
( http: // creativecommons.org / licenses / by / 3.0 / ). ntroduction 
Reactive oxygen species (ROS) are a byproduct of metabolism, be- 
ng produced, for example, during electron transfer in mitochondrial 
espiration [ 1 ]. ROS can serve as signaling molecules for metabolic 
rocesses including PI3K- and AMPK-independent glucose transport 
 2 ], PGC α-stimulated mitochondrial biogenesis [ 3 ], and regulation of 
uscle-derived cytokines [ 4 ]. However, prolonged oxidative stress, 
s apparent in obesity and metabolic syndrome, is associated with 
n elevation in reactive oxygen species (ROS) [ 5 ]. Elevated levels of 
OS have been shown to be associated with insulin resistance [ 6 ], 
 key feature of type 2 diabetes mellitus [ 7 ]. For example, mice fed 
 high-fat diet to induce insulin resistance displayed increased ROS 
evels in adipocytes and skeletal muscle [ 8 ]. Intriguingly, treatment 
ith an antioxidant prevented insulin resistance caused by a high fat 
iet [ 8 ]. 
Glucose transporter 1 (GLUT1) transports glucose [ 9 ] and dehy- 
roascorbic acid (DHA) [ 10 ], the oxidized form of ascorbate. Both 
lucose and ascorbic acid have roles in antioxidant defense. Glu- 
ose, in the form of glucose 6-phosphate, is the ﬁrst substrate in 1 Current address: Saint Louis University School of Medicine, USA. 
2 Current address: Division of Endocrinology, Stanford University, USA. 
* Corresponding author. 
E-mail address: ﬁsherjs@slu.edu (J.S. Fisher). 
213-2317/ $ - see front matter c © 2014 The Authors. Published by Elsevier B.V. This is an op
.0 / ). 
ttp://dx.doi.org/10.1016/j.redox.2014.03.004 the pentose phosphate pathway, which generates the electron car- 
rier NADPH [ 11 ]. NADPH donates electrons to antioxidant pathways 
such as those including glutathione reductase, thioredoxin reductase, 
or reduction of DHA to ascorbate, and these pathways in turn de- 
press ROS levels [ 12 , 13 ]. Previous work has shown that increased 
activity of ataxia telangiectasia mutated (ATM) leads to increased 
GLUT1-mediated glucose and DHA transport in a mechanism that 
likely involves phosphorylation of GLUT1 at serine 490 (S490) [ 14 ]. 
Thus, it seems possible that ATM, which acts as a ROS sensor and 
activates glucose 6-phosphate dehydrogenase (G6PDH) in response 
to oxidative stress, could also promote antioxidant defense through 
regulation of GLUT1. 
The objective of the present study was to determine whether 
GLUT1 contributes to regulation of ROS levels in myoblasts. Here we 
show that inhibition of GLUT1, but not GLUT4, increases ROS. Addi- 
tionally, activation of ATM decreases ROS, except in cells expressing a 
GLUT1 serine–alanine mutation at an ATM target site, S490. Further, 
inhibition of ATM increases ROS, except in cells expressing GLUT1 
with an ATM target site mutated to aspartate (S490D). Finally, we 
found that expression of GLUT1-S490D protects against ROS-induced 
insulin resistance. en access article under the CC BY license ( http: // creativecommons.org / licenses / by / 
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 Materials and methods 
Materials 
Phosphate buffered saline (PBS), trypsin, Dulbecco ’ s modiﬁed
Eagle ’ s medium (DMEM), antimycin A, phloretin, and fasentin were
acquired from Sigma Aldrich (St. Louis, MO, USA). The general ROS
and superoxide speciﬁc ﬂuorescent probes, CM-H2DCFDA (DCFDA)
and Mitosox Red, respectively, were purchased from Life Technolo-
gies, Invitrogen (Eugene, OR, USA). Doxorubicin was purchased from
Sigma-Aldrich (St. Louis, MO, USA). The ATM inhibitor KU55933 (KU)
[ 15 ] was a gift from KuDos Pharmaceuticals, Ltd. (Cambridge, UK). A
second ATM inhibitor, CP466722 (CP) [ 16 ], was obtained from Pﬁzer
(Groton, CT). Antibodies against phosphorylated Akt S473 and Akt
were obtained from Cell Signaling Technology (Danvers, MA, USA).
Antibodies against GAPDH (conjugated to horseradish peroxidase)
and phosphorylated rat / mouse IRS-1 Y612 (equivalent to Y608 in
murine IRS-1) were purchased from Sigma-Aldrich (St. Louis, MO,
USA). 
Cell culture 
L6 myoblasts were bought from the American Type Culture Col-
lection (Manassas, VA). DMEM containing 10% FetalPlex (Gemini Bio-
Products, Woodland, CA) and 1% antibiotic–antimycotic solution were
used to culture the L6 myoblasts at 37 ◦C in 5% CO 2 . 
GLUT1 constructs and transfections 
The FLAG-GLUT1 construct [ 17 ], containing an exofacial FLAG epi-
tope in the ﬁrst extracellular loop, was kindly contributed by Jeffrey
Rathmell (Duke University). Site mutants, GLUT1-S490A and GLUT1-
S490D, were generated as described previously [ 14 ]. Compared to
myotubes, L6 myoblasts display depressed GLUT3 expression [ 18 ].
Thus, we used myoblasts instead of myotubes to minimize any po-
tential role of GLUT3, a low afﬁnity glucose and DHA transporter, in
the outcome measures. 
Reactive oxygen species assays 
L6 myoblasts were loaded with ﬂuorescent probes (primarily
10 μM DCFDA but for one experiment 5 μM Mitosox Red in serum
free DMEM) for 30–60 min, washed with PBS to clear away phe-
nol red, and incubated in HEPES buffered saline (HBS: 5 mM glu-
cose, 20 mM HEPES, 140 mM NaCl, 5 mM KCl, 2.5 mM MgSO 4 , and
1 mM CaCl 2 ) to obtain a baseline ﬂuorescence reading. DCFDA has an
excitation / emission of 485 / 528 nm. MitoSox Red has an excitation /
emission of 485 / 590 nm. DCFDA is a general ROS probe [ 19 ]. Mi-
toSox Red is a ﬂuorogenic dye that accumulates in mitochondria and
purportedly detects superoxide anions [ 20 ]. After the baseline read-
ing, the L6 myoblasts were incubated in serum-free media plus and
minus the appropriate treatment, then a second ﬂuorescence read-
ing was taken followed immediately by exposure to ROS inducers,
antimycin A (Ant-A) and pyrogallol (PG). Ant-A stimulates mitochon-
drial superoxide production via disruption of cytochrome c reductase
in the electron transport chain [ 21 ]. Pyrogallol generates superoxide
by nonenzymatic reaction with oxygen [ 22 ]. Finally, a kinetic ﬂuores-
cence reading was taken. A portion of the plates contained no cells or
non-loaded cells as negative controls. 
Insulin action experiments 
L6 myoblasts transiently transfected with FLAG-GLUT1 constructs
were serum starved in HBS for 2 h and then treated plus or minus
100 nM insulin and 50 μM pyrogallol, a ROS generator, for 1 h. Subse-
quently, the cells were washed twice with phosphate buffered saline(PBS) then subjected to either a Western blot analysis or glucose
transport assay (both described below). 
Western blot analysis 
L6 myoblasts transiently transfected with FLAG-GLUT1 constructs
and incubated as explained above were subjected to Western blot
analysis as described previously [ 14 ]. 
Transport assays for cultured myoblasts 
L6 myoblasts, treated as explained in insulin action experiments
above, were exposed to 2-deoxy-glucose (2DG) transport media
(0.5 μCi / ml 3H-labeled 2DG, 10 μM 2DG, dissolved in glucose-free
HBS) for 10 min. An ice-cold 0.9% saline solution was used to wash
the cells. The cells were then incubated with lysis buffer (0.2% SDS
and 0.2 N NaOH) for 30 min and processed for scintillation counting
as described previously [ 14 ]. A BCA assay was performed using the
samples to determine protein content. To account for non-speciﬁc
2DG uptake, a subgroup of the cells was treated in the presence of
10 μM cytochalasin B. Cytochalasin B prevents transport by GLUTs
[ 23 ]. 
Statistical analysis 
Univariate one-way analysis of variance (ANOVA) with a signif-
icance determined as p < 0.05 was used to analyze the data. The
software used was SPSS Statistics 21.0 (IBM, Armonk, NY, USA). 
Results 
Inhibition of GLUT1 elevates ROS levels 
The oxidative state of the cell is maintained by a balance between
antioxidant and pro-oxidant levels. In cultured muscle cells, GLUT1
and GLUT4 transport glucose [ 23 ] and DHA [ 24 ], both of which can
aid in antioxidant defense [ 11 , 13 ]. To determine the effects of GLUT1
inhibition on ROS levels, L6 myoblasts that had been loaded with
DCFDA, a ﬂuorescent ROS probe, were incubated in media plus and
minus GLUT1 inhibitors, and then oxidative stress was induced by
antimycin A (Ant-A) or pyrogallol (PG). GLUT1 inhibition with 80 μM
fasentin increased both Ant-A- and PG-induced ROS levels (30–40%,
p < 0.05) ( Fig. 1 A and B). GLUT1 inhibition with 100 μM phloretin
raised Ant-A-induced ROS by 20% and PG-induced ROS levels by 2-
fold ( p < 0.05) ( Fig. 1 C and D). These data suggest that GLUT1 plays a
role in the regulation of ROS levels. 
To determine whether GLUT4 plays a role in regulation of ROS
in muscle cells, DCFDA loaded L6 myoblasts were incubated in the
presence or absence of 100 μM indinavir, which inhibits GLUT4 but
not GLUT1, and then oxidative stress was induced by Ant-A or PG.
From 4 min post-induction and beyond, indinavir treated muscles
displayed no signiﬁcant change in Ant-A or PG-induced ROS levels
from control muscle cells ( Fig. 1 E and F). Thus, in muscle cells, GLUT4
does not play a role in regulation of ROS levels. Together, the data
suggest that GLUT1 plays a more prominent role in regulation of ROS
than does GLUT4. 
A carboxy terminus amino acid residue, GLUT1-S490, regulates ROS 
levels 
GLUT1 has a cytosolic N-terminus, 12 membrane-spanning he-
lices, and a cytosolic 42 amino acid C-terminus [ 25 ]. The c-terminus
of GLUT1 contains a PDZ binding motif [ 26 ]. Removal of the last
four amino acids which make up the GLUT1 PDZ binding motif results
in GLUT1 being internalized from the plasma membrane [ 26 ]. Previ-
ous work has shown that GLUT1-S490, an ATM target within the PDZ
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Fig. 1. Inhibition of GLUT1 increases ROS levels. L6 myoblasts were subjected to a DCFDA ROS assay in the presence or absence of (A) GLUT1 inhibitor, 80 μM fasentin with 
induction of ROS by 100 μM antimycin A (AntA), (B) 80 μM fasentin with 50 μM pyrogallol (PG), a superoxide generator, (C) GLUT1 inhibitor, 100 μM phloretin, with induction of 
ROS by 100 μM AntA, (D) 100 μM phloretin with 50 μM PG, and (E) 100 μM indinavir, which inhibits GLUT4, with induction of ROS by Ant-A or (F) by PG. ( n = 6 / group. Differences 
are statistically signiﬁcant for all time points after time 0, p < 0.05. Subpanels E and F do not display signiﬁcant differences, except 1F at 2 min, p < 0.05). 
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 14 ]. For example, expression of GLUT1-S490A decreases glucose and 
HA transport, cell surface localization of GLUT1, whereas GLUT1- 
490D increases glucose and DHA transport and cell surface GLUT1. 
hese alterations are concomitant with changes in association of the 
DZ protein GIPC1 with GLUT1. This ATM target site of GLUT1, S490, 
s not present in GLUT4. 
To determine the role of GLUT1-S490 in regulation of ROS levels, 
6 myoblasts transiently transfected with FLAG-GLUT1 constructs or 
LAG-GLUT1 constructs containing a point mutation of GLUT-S490 
ere subjected to DCFDA ROS assays or in one experiment MitoSox- 
ed ROS assays. GLUT1-S490A mutants exhibited enhanced basal ROS 
evels as assessed with DCFDA (63%, p < 0.05) and enhanced basal 
itosox Red signal (25%, p < 0.05) ( Fig. 2 A). Fluorometric measures 
ith Mitosox Red were not as robust as those with DCFDA, so all 
ubsequent measures were with DCFDA. The Mitosox Red measures 
re listed as “superoxide levels” in panel A, although it must be ac- 
nowledged that Mitosox Red is by no means speciﬁc for superoxide, 
eacting, for example, with heme-containing proteins [ 27 ]. 
There was nearly a ten-fold increase in Ant-A-induced ROS levels 
 p < 0.05) ( Fig. 2 B), and a 5-fold increase in PG-induced ROS levels compared to controls ( p < 0.05) ( Fig. 2 C). GLUT1-S490D mutants 
displayed diminished basal ROS levels (12%, p < 0.05) ( Fig. 2 D), and 
both Ant-A- and PG-induced ROS levels were lowered by roughly 
50% in cells expressing GLUT1-S490D( p < 0.05) ( Fig. 2 E and F). These 
ﬁndings suggest that phosphorylation of GLUT1-S490 could play a 
role in decreasing oxidative stress. 
ATM may play a role in GLUT1-mediated ROS regulation 
Previous work has shown that GLUT1-mediated glucose and DHA 
transport is regulated by ATM [ 14 ]. To decipher whether ATM in- 
hibitors that were previously shown to lower GLUT1-mediated trans- 
port would increase ROS levels, as GLUT1 inhibition did ( Fig. 1 ), L6 my- 
oblasts were incubated in the presence and absence of ATM inhibitors 
and subjected to a DCFDA ROS assay. Basal ROS levels were elevated 
in L6 myoblasts exposed to ATM inhibitors, 6 μM CP and 10 μM KU, 
compared to controls (43% and 20%, respectively, p < 0.05) ( Fig. 3 A 
and B). ATM inhibition with 6 μM CP resulted in a 2-fold increase in 
Ant-A- and PG-induced ROS levels in L6 myoblasts ( p < 0.05) ( Fig. 3 C 
and D). 
To determine if these ATM effects on regulation of ROS levels 
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Fig. 2. GLUT1-S490 mutations affect ROS levels. L6 myoblasts transiently transfected with FLAG-GLUT1 constructs or FLAG-GLUT1-S490 point mutation constructs were loaded 
with the general ROS ﬂuorescent probe, DCFDA (for all data except the right panel of A), or a purported superoxide probe that accumulates in mitochondria, MitoSox Red (right 
panel of A only), and ﬂuorescent readings were taken. (A) Cells expressing wild-type GLUT1 (WT) vs. GLUT1-S490A under basal conditions, (B) with 100 μM Ant-A induction of 
ROS or (C) with induction of ROS by 50 μM PG. (D) WT vs. GLUT1-S490D mutants under basal conditions, (E) with 100 μM Ant-A induction of ROS, or (F) with induction of ROS by 
50 μM PG. ( n = 6 / group, p < 0.05 for all panels. Differences are statistically signiﬁcant for all time points after time 0, p < 0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 might involve a direct effect on GLUT1, transiently transfected FLAG-
GLUT1 L6 myoblasts expressing wild-type GLUT1 or GLUT1-S490A
were loaded with DCFDA, incubated in media plus and minus 10 μM
KU (an ATM inhibitor), and then exposed to superoxide generator,
pyrogallol (50 μM). Cells expressing wild-type GLUT1 and treated
with KU displayed a 28% increase in PG-induced ROS levels ( p < 0.05,
Fig. 3 E). However, ATM inhibition with KU had no effect on cells
expressing GLUT1-S490D ( Fig. 3 E). These ﬁndings suggest that ATM
regulates ROS levels in a GLUT1-S490 dependent manner. 
Previous work has shown that ATM activation promotes GLUT1-
mediated transport in skeletal muscles and cultured muscle cells [ 14 ].
To examine the role of ATM activation on ROS levels in muscle cells, a
DCFDA ROS assay was performed after exposure of myoblasts to the
ATM activator doxorubicin (DXR). L6 myoblasts incubated in 1 μM
DXR displayed lowered basal and PG-induced ROS levels compared
to vehicle-treated (0.1% DMSO) controls (25% and 65%, respectively,
p < 0.05) ( Fig. 4 A and B). PG-induced ROS levels were markedly
increased in cells transfected with GLUT1-S490A compared to cells
transfected with wild-type GLUT1 ( p < 0.05) ( Fig. 4 C). Furthermore,
DXR had no effect on ROS levels in cells expressing GLUT-S490A ( Fig.
4 C). These data suggest that ATM activation could decrease ROS in a
mechanism involving GLUT1-S490 phosphorylation. ROS and insulin action 
Elevated levels of hydrogen peroxide interfere with insulin action,
as demonstrated by weakened insulin-stimulated GLUT4 transloca-
tion in 3T3-L1 adipocytes after long-term exposure to H 2 O 2 [ 28 ].
Another study showed that ROS-induced insulin resistance caused
by TNF- α and dexamethasone could be reversed by suppression of
ROS via antioxidants and transgenes promoting antioxidant defense
[ 29 ]. GLUT1-S490D has been shown to increase GLUT1-mediated glu-
cose and DHA transport [ 14 ] and also to decrease ROS levels ( Fig. 2 B,
D and F). To determine if GLUT1-S490D could prevent ROS-induced
insulin resistance, L6 myoblasts transfected with FLAG-GLUT1 and
FLAG-GLUT1-S490D mutants were incubated in media in the pres-
ence and absence of both insulin and PG then subjected to Western
blot analysis exploring insulin signaling pathways. L6 myoblasts ex-
pressing FLAG-GLUT1 (wild type) treated with insulin displayed a 10-
fold increase in phosphorylated Akt serine 473 (p-Akt S473) levels
and a 4-fold rise in phosphorylated insulin receptor substrate 1 tyro-
sine 612 (p-IRS-1) compared to FLAG controls ( p < 0.05) ( Fig. 5 A and
B). However, the insulin-induced increase in p-Akt S473 was nearly
fully prevented by exposure to PG ( p < 0.05) ( Fig. 5 A). Likewise, the
4-fold escalation in p-IRS-1 caused by insulin was also diminished by
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Fig. 3. GLUT1-S490D prevents increases in ROS when ATM is inhibited. L6 myoblasts were subjected to a DCFDA ROS assay in the presence or absence of (A) ATM inhibitor, 6 μM 
CP466722 (CP), (B) ATM inhibitor, 10 μM KU55933 (KU), (C) 6 μM CP with 100 μM Ant-A induction of ROS, and (D) 6 μM CP with induction of ROS by 50 μM PG. (E) L6 myoblasts 
transiently transfected with FLAG-GLUT1 (WT) or FLAG-GLUT1-S490D (S490D) constructs were treated plus and minus 10 μM KU. ( n = 6 / group, * p < 0.05 for all panels. Differences 
are statistically signiﬁcant for all time points after time 0, p < 0.05, except for lines that visually overlap). 
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tG ( p < 0.05) ( Fig. 5 B). Thus, pyrogallol decreases insulin action in 
6 myoblasts. Strikingly, expression of GLUT1-S490D prevented the 
G-induced decreases in insulin-stimulated p-Akt S473 and p-IRS-1 
evels ( p < 0.05) ( Fig. 5 A and B). In accordance with these ﬁndings, PG 
ecreased insulin-stimulated glucose transport in myoblasts trans- 
ected with the wild-type GLUT1 construct, but insulin action was 
ormal in myoblasts transfected with the GLUT1-S490D construct 
 Fig. 5 C). Expression of the GLUT1 transgenes was similar for wild- 
ype GLUT1 and GLU1-S490D as demonstrated by the similar FLAG signal. Taken together, the data in Fig. 5 suggest that GLUT1-S490D 
prevents ROS-induced insulin resistance in L6 myoblasts. 
Discussion and conclusions 
The ﬁndings presented in this study show that GLUT1 plays a role 
in regulation of ROS levels in muscle cells. For example, inhibition of 
GLUT1-but not inhibition of GLUT4-increased ROS levels caused by 
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Fig. 4. GLUT1-S490A prevents the ROS-lowering effect of doxorubicin. L6 myoblasts underwent a DCFDA ROS assay in the presence or absence of ATM activator, 1 μM doxorubicin 
(DXR), and ﬂuorescent readings were taken (A) under basal conditions and (B) after exposure to PG. (C) Myoblasts expressing FLAG-GLUT1(WT) and FLAG-GLUT1-S490A (S490A) 
were treated plus and minus 1 μM DXR, an ATM activator. ( n = 6 / group, * p < 0.05 for all panels. Differences are statistically signiﬁcant for all time points after time 0, p < 0.05, 
except for lines that visually overlap). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 challenge with pyrogallol or antimycin A. Site mutation of GLUT1-
S490, a known ATM phosphorylation target, to alanine (S490A) aug-
mented ROS levels; in contrast, mutation of this ATM target site to
aspartic acid (S490D) decreased ROS levels. Inhibition of ATM in-
creased ROS, but not in cells expressing GLUT1 mutated to mimic
phosphorylation at an ATM target site (S490D). Conversely, the ATM
activator doxorubicin decreased ROS, but not in myoblasts express-
ing GLUT1-S490A. Finally, insulin resistance caused by a superoxide
generator was prevented by expression of GLUT1-S490D. Together,
the data suggest the novel idea that GLUT1 plays a role in antioxidant
defense and also functions to maintain insulin action in the face of
oxidative stress.  Insulin exerts its effects of lowering blood glucose levels by acti-
vating a signaling cascade that results in the translocation of GLUT4
[ 30 ]. IRS-1 undergoes tyrosine phosphorylation after insulin binding
to the insulin receptor activates the receptor ’ s kinase activity [ 31 ].
Phosphorylation at Tyr 612 (corresponding to Y608 of murine IRS-1)
and several other tyrosine residues of IRS-1 recruits other proteins
to propagate the insulin signal [ 31 ]. Downstream of IRS-1, Akt medi-
ates effects of insulin such as regulation of insulin-stimulated GLUT4
translocation [ 32 ]. Phosphorylation at S473 of Akt leads to activation
of Akt kinase activity [ 33 ]. Here we show that GLUT1-S490D was able
to rescue the ROS-induced decrease in insulin signaling at IRS-1 and
Akt. 
ATM is well known for its nuclear role of sensing and commencing
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Fig. 5. GLUT1-S490D prevents ROS-induced insulin resistance. L6 myoblasts tran- 
siently transfected with FLAG-GLUT1 (WT) constructs or FLAG-GLUT1-S490D(SD)point 
mutation constructs were treated plus and minus insulin (INS) and pyrogallol (PG), a 
superoxide generator, then subjected to (A) Western blot analysis probing for phos- 
phorylated Akt S473 (p-Akt S473) and Akt as a loading control or (B) phosphorylated 
insulin receptor substrate 1 (p-IRS-1) and glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) as a loading control, and (C) a glucose transport assay ( n = 3 / group for the 
Western analysis and 6 / group for the transport assay, * p < 0.05 compared to WT, 
† p < 0.05 compared to INS, and ‡ p < 0.05 compared to S490D for all panels). 
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reaks recruit and activate ATM which in turn coordinates a signaling 
ascade that solicits DNA repair machinery and cell cycle checkpoint 
roteins to repair the damaged DNA or initiate apoptosis [ 35 ]. Aside 
rom ATM ’ s nuclear role, several studies have revealed that ATM dis- 
lays cytosolic localizations [ 36 , 37 ], where ATM plays a role in ROS 
ensing and signaling [ 37 ]. ROS activate ATM via autophosphorylation of S1981 in a DNA damage-independent manner initiating a cytoso- 
lic signaling cascade that inhibits mTORC1 in an LKB1-AMPK-TSC2 
dependent fashion [ 38 ]. Decreased mTOR activity is associated with 
decreased oxidative phosphorylation [ 39 ] which in turn lowers ROS. 
In an independent process, reactive oxygen species directly activate 
ATM, leading to subsequent activation of G6PDH and an increase in 
potential to reduce ROS [ 40 ]. Here we propose a novel way for ATM 
to reduce ROS via regulation of GLUT1. 
Antioxidant defense proteins include single molecule antioxidants 
as well as intricate antioxidant enzyme systems [ 41 ]. Ascorbic acid 
[ 42 ], α-tocopherol (vitamin E) [ 43 ], β-carotene [ 44 ], and lipoic acid 
[ 45 ] are among the prominent small molecule antioxidants in the 
cell. The antioxidant enzyme systems include glutathione systems, 
superoxide dismutases, catalases, and peroxiredoxins [ 46 , 47 ]. The 
glutathione systems are composed of glutathione reductases, per- 
oxidases, and S-tranferases, and have the ability to rapidly reduce 
DHA to ascorbate [ 48 ]. As an adaptive response, under immunologi- 
cal oxidative stress, hepatic endothelial cells display increased levels 
of GLUT1 and G6PDH [ 49 ]. G6PDH is the rate limiting enzyme in 
the pentose phosphate pathway [ 50 ], which produces NADPH [ 50 ]. 
All of the above listed antioxidant enzymes require NADPH directly 
or indirectly for functionality [ 49 ]. Through the increased activity of 
GLUT1 to bring in glucose to serve as a substrate (when converted to 
glucose-6-phosphate) for the pentose phosphate pathway to produce 
more NADPH, hepatic endothelial cells have developed a mechanism 
to reduce ROS and decrease oxidative stress [ 51 ]. Thus, GLUT1 expres- 
sion has previously been shown to be associated with redox status. By 
use of GLUT1 inhibitors and site mutations that alter GLUT1-mediated 
transport, the current study has elevated GLUT1 from a factor associ- 
ated with oxidative defense to a protein that plays a role in regulation 
of ROS levels. 
In summary, a role of GLUT1 in regulation of ROS levels has been 
elucidated by means of GLUT1 inhibitors that increase ROS and ex- 
pression of GLUT1 with mutations at an ATM target site that prevent 
(S490A) or mimic (S490D) phosphorylation and increase or decrease 
ROS, respectively. Notably, the ATM activator doxorubicin decreases 
ROS except in cells that express GLUT1-S490A, while inhibition of 
ATM increases ROS except in cells transfected with GLUT1S490D. 
Furthermore, expression of GLUT1-S490D protects cells against ROS- 
mediated insulin resistance. Thus, the ﬁndings suggest the novel idea 
that GLUT1 plays roles in regulation of ROS and maintenance of insulin 
action under conditions of oxidative stress. 
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